Publications by authors named "J Jirsa"
Background: A subcutaneous formulation of infliximab (IFX-SC) approved to treat patients with inflammatory bowel disease may offer improved efficacy versus intravenous infliximab.
Methods: Patients with refractory Crohn's disease (CD, = 32) previously treated unsuccessfully with at least 2 biologics were treated with IFX-SC and followed from baseline at Week 0 (W0) to Week 30 (W30). The study's primary endpoint was the treatment's persistence at W30, while secondary goals included the analysis of serum infliximab trough levels (TL IFX), dynamics of anti-IFX antibodies (ATIs), and clinical, serum and fecal markers of CD activity during IFX-SC treatment.
Article Synopsis
- The study compares the long-term effectiveness of originator-adalimumab and its biosimilar, SB5-adalimumab, in treating Crohn's disease patients who switched medications versus those who remained on the originator over a period of 104 weeks.
- At 52 weeks, clinical disease activity scores showed no significant difference between the two groups, with similar outcomes on related biological measures.
- However, treatment persistence was notably lower for the SB5-adalimumab group, with local skin reactions being a common reason for discontinuation.